Hologic Posts Loss In Q3 - Quick Facts

(RTTNews) - Hologic, Inc. (HOLX) reported a third-quarter net loss of $10.95 million or $0.04 per share, compared to net income of $23.59 million or $0.09 per share, a year ago. Non-GAAP net income was $103.23 million or $0.38 per share, for the quarter.

On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $0.37 for the quarter. Analysts' estimates typically exclude special items.

Revenues rose to $626.14 million, from $470.23 million last year. Analysts expected revenue of $626.84 million for the quarter.

Hologic said the overall revenue increase was partially offset by lower year-over-year sales of: Legacy Hologic Diagnostics products, primarily ThinPrep; NovaSure endometrial ablation systems; 2D Selenia and 2D Dimensions mammography systems; and Adiana permanent contraception systems due to the decision to discontinue this product line.

The company expects fourth-quarter revenues of $615 million to $625 million. The company expects non-GAAP adjusted EPS of $0.36 to $0.37. Analysts expect the company to report fourth-quarter profit per share of $0.44 on revenue of $651.34 million.

Hologic adjusted its fiscal 2013 non-GAAP revenues to a range of $2.505 billion to $2.515 billion from a range of $2.53 billion to $2.55 billion. The company now expects non-GAAP EPS of $1.46 to $1.47, compared to a prior guidance of $1.54 to $1.56. Analysts expects the company to report fiscal 2013 profit per share of $1.54 on revenue of $2.54 billion.